RTP Mobile Logo

5MJC MDS/AML 12: New Prognostic Markers in Acute Myeloid Leukemia (AML)

New Prognostic Markers in Acute Myeloid Leukemia (AML)

5MJC MDS/AML 10: Phase II Study of Clofarabine for Older Patients with Treatment-Naïve AML

Phase II Study of Clofarabine for Older Patients with Treatment-Naïve AML

5MJC MDS/AML 6: A Prognostic Model for MDS that Accounts for Events Not Considered by the International Prognostic Scoring System (IPSS)

A Prognostic Model for MDS that Accounts for Events Not Considered by the International Prognostic Scoring System (IPSS)

5MJC MDS/AML 9: Three Alternate Dosing Schedules of Azacitidine for MDS

Three Alternate Dosing Schedules of Azacitidine for MDS

5MJC MDS/AML 8: EORTC-06011: Low-Dose Decitabine versus Best Supportive Care for Elderly Patients with Intermediate- or High-Risk MDS

EORTC-06011: Low-Dose Decitabine versus Best Supportive Care for Elderly Patients with Intermediate- or High-Risk MDS

5MJC MDS/AML 5: Myelodysplastic Syndromes

Myelodysplastic Syndromes

5MJC MDS/AML 7: Azacitidine Before Allogeneic Hematopoietic Cell Transplantation (AHCT) for Myelodysplasias

Azacitidine Before Allogeneic Hematopoietic Cell Transplantation (AHCT) for Myelodysplasias

5MJC MDS/AML 4: Anthracycline Dose Intensification in Acute Myeloid Leukemia (AML)

Anthracycline Dose Intensification in Acute Myeloid Leukemia (AML)

5MJC MDS/AML 3: Outcome of Myelodysplastic Syndrome (MDS) with and without Chromosome 5 Abnormalities

Outcome of Myelodysplastic Syndrome (MDS) with and without
Chromosome 5 Abnormalities

5MJC MDS/AML 2: Efficacy of Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS)

Efficacy of Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS)

5MJC MDS/AML 1: Cooked and Noncooked Diets in Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy

Cooked and Noncooked Diets in Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy

5MJC RCCU 4: Pazopanib in Patients with Treatment-Naïve or Cytokine-Pretreated Advanced RCC

Pazopanib in Patients with Treatment-Naïve or Cytokine-Pretreated Advanced RCC

5MJC RCCU 3: Sunitinib Continuous 37.5 mg/Day Dosing in Cytokine-Refractory Metastatic RCC

Sunitinib Continuous 37.5 mg/Day Dosing in Cytokine-Refractory Metastatic RCC

5MJC RCCU 2: Everolimus in Patients with Cytokine-Pretreated mRCC

Everolimus in Patients with Cytokine-Pretreated mRCC

5MJC RCCU 1: Presurgical Feasibility of Bevacizumab for Nephrectomy-Eligible, Treatment-Naïve Patients with Metastatic Renal Cell Carcinoma

Presurgical Feasibility of Bevacizumab for Nephrectomy-Eligible, Treatment-Naïve Patients with Metastatic Renal Cell Carcinoma